Randomized Controlled Trial of Prophylactic Antibiotics for Dog Bites with Refined Cost Model by Quinn, James V. et al.
Western Journal of Emergency Medicine  435  Volume XI, no. 5  :  December 2010
oRiginal ReseaRCh
Randomized Controlled Trial of Prophylactic Antibiotics for 
Dog Bites with Refined Cost Model
James V. Quinn, MD, MS*
Daniel McDermott, MD†
Jennifer Rossi, MD*
John Stein, MD†
Nathan Kramer, BS†
*Division of Emergency Medicine, Stanford University
†Department of Emergency Medicine, University of California, San Francisco
Supervising Section Editor: Sukhjit S. Takhar, MD
Submission history: Submitted June 22, 2009; Revision Received September 2, 2009; Accepted January 18, 2010
Reprints available through open access at http://escholarship.org/uc/uciem_westjem
Objective: The aim of this study was to determine the rate of infection at which it is cost-effective to 
treat dog bite wounds with antibiotics. 
Methods: Our study was composed of two parts. First we performed a randomized, double-
blind controlled trial (RCT) to compare the infection rates of dog bite wounds in patients given 
amoxicillin-clavulanic acid versus placebo. Subjects were immunocompetent patients presenting 
to the emergency department (ED) with dog bite wounds less than 12 hours old without suspected 
neurovascular, tendon, joint or bone injury, and who had structured follow-up after two weeks. 
Second, we developed a cost model with sensitivity analysis to determine thresholds for treatment.
Results: In the RCT, primary outcomes were obtained in 94 patients with dog bites. The overall 
wound infection rate at two weeks was 2% [95% CI 0 to 7%]. Two of 46 patients (4%) receiving no 
antibiotics developed infections, while none of the 48 patients (0%) receiving prophylactic antibiotics 
developed an infection (absolute reduction 4% [95% CI -1.0 to 4.5%]). Using a sensitivity analysis 
across a rate of infections from 0-10%, our cost model determined that prophylactic antibiotics were 
cost effective if the risk of wound infection was greater than 5% and antibiotics could decrease that 
risk by greater than 3%. 
Conclusion: Our wound infection rate was lower than older studies and more in line with current 
estimates. Assuming that prophylactic antibiotics could provide an absolute risk reduction (ARR) of 
3%, it would not be cost effective to treat wounds with an infection rate of less than 3% and unlikely 
that the ARR would be achievable unless the baseline rate was greater than 5%, suggesting that 
only wounds with greater than 5% risk of infection should be treated. Future work should focus on 
identifying wounds at high-risk of infection that would benefit from antibiotic prophylaxis. [West J 
Emerg Med. 2010; 11(5):435-441.]
INTRODUCTION
Background
Dog bites are a common public health problem, and 
nearly five million people are bitten each year in the United 
States.1 Although only one-fifth of bite victims seek medical 
care, these patients account for nearly one thousand daily 
emergency department (ED) visits in this country.1,2
The primary morbidity associated with dog bites is 
their infection rate, which is generally higher than normal 
wounds.3-7 However, it is unclear whether bite wounds 
should be treated with prophylactic antibiotics. There are 
numerous contradictory studies regarding the exact incidence 
and true risk of infection. A meta-analysis of prior studies 
recommended the administration of prophylactic antibiotics, 
yet this study had several significant limitations.5 For example, 
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different methodologies, lacked a standardized definition for 
wound infection, used a variety of antibiotics (often those 
to which the most common organisms from bites are not 
susceptible), and contained large range of infection rates in the 
control groups (from 3.2% to 45.8%).3,5,8-9 Conversely, a more 
recent Cochrane review9 of the same randomized controlled 
trials concluded there was no strong evidence for treating 
wounds with prophylactic antibiotics. The routine use of 
antimicrobials for such a common but controversial indication 
is concerning given the risks of medication side effects, 
increased resistance, and cost of approximately $30 million 
dollars per year.10
Goals of this investigation
The first objective was to determine the infection rate at 
which antibiotics are clinically warranted and cost-effective 
using a cost model and sensitivity analysis based on existing 
data from the literature and known costs associated with 
various treatments. The second objective was to estimate 
current rates of infection and verify previously published 
infection rates used in our model by conducting a randomized 
controlled trial of dog bite wounds treated with and without 
oral prophylactic antibiotics.
METHODS
Decision Tree Cost Model
A cost decision tree model based on all clinical outcomes 
and scenarios was developed using TreeAge Data 4.0 (Figure 
1). This tree model mapped out all inpatient and outpatient 
treatment options, outcomes and side effects for patients 
sustaining dog bite wounds. The following pathways and 
assumptions were made: 1) patients would have the same 
chance of being treated as an outpatient or an inpatient once 
diagnosed with an infection regardless of whether they were 
on prophylactic antibiotics; 2) wound infections in patients on 
prophylactic antibiotics did not alter the chance of outpatient 
recovery, inpatient recovery, inpatient complication rates, 
chance of death, chance of disability or side effects; and 3) 
subsequent outpatient care and follow-up was included in the 
cost of inpatient care given the high cost of inpatient care and 
the low cost and variability of subsequent outpatient follow-
up. Table 1 lists the estimates made regarding effectiveness 
and clinical outcomes in the cost model. It also outlines the 
source/reason for these estimates as well as the frequencies 
and ranges tested in the analysis. The legal costs resulting 
from liability of untreated wounds that become infected were 
omitted from this analysis since wound infection is an 
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Figure 1. Cost model for the use of prophylactic antibiotics for dog bites
Inpt, Inpatient; Inf, infection; Outpt, Outpatient; Rx, perscriptionWestern Journal of Emergency Medicine  437  Volume XI, no. 5  :  December 2010
expected complication and the treatment unproven. Of note, 
the highest liability from wound treatment is missed foreign 
body.11
The costs of cellulitis, septicemia, scar revision and 
incision and drainage of the skin were gathered from the 
Healthcare Costs and Utilization Project 2003 Nationwide 
Inpatient Sample and the costs of Outpatient Visit level 3 on 
the 2005 Medicare Fee Schedule.12 These were then adjusted 
for inflation to 2006. The average price of amoxicillin-
clavulanic acid is $5 a pill (range $2-7) .13 The costs of these 
items are detailed in Table 2.
Sensitivity Analysis
The sensitivity analysis was performed using this decision 
tree. It calculated and compared the baseline treatment costs 
of all dog bite wound infections with the collective treatment 
costs of administering prophylactic antibiotics and treating 
the non-preventable infections. This calculation was run over 
varying baseline infection rates and percentage of wound 
complications prevented. Costs were based on the rate of each 
infection and the cost of each intervention needed to treat 
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Table 1. Estimates of antibiotic effectiveness and clinical outcomes in the cost model
Variable Estimate Evidence Range Analyzed Source
Baseline infection rate facial bites (FaceNoRxInf) 10% Retrospective review  5% - 10% [3] [6] 
Infection Rate - prophylactic antibiotics – facial bites 
(FaceRxInf)
5.6% 
(95% CI 3.8 –8.2%)
Meta-analysis of RCT 3.2% - 10% [5]
Baseline infection rate
hand bites (HandNoRxInf)
36% Retrospective Review 10% - 50% [3] [6] 
Infection rate - prophylactic antibiotics – hand bites 
(HandRxInf)
8.3%
(95% CI 1.8 – 34.2%)
Meta-analysis of RCT 18% - 34.2% [5]
Baseline infection rate
other area (extremity and trunk) (OtherNoRxInf)
17% Retrospective Review 10% - 30% [3] [6] 
Infection rate - prophylactic antibiotics – other areas 9.5%
(95% CI 6.5% - 13.95)
Meta-analysis of RCT 6.5% - 14% [5]
% Facial bites 50% Survey estimates N/A [2]
% Hand bites 30% Survey estimates N/A [2]
% Other  20% Survey estimates N/A [2]
% of infected wounds considered for outpt Rx 
(OutPtRx)
90% Physician Opinion 50% - 90%
Failure rate of outpt antibiotics (Fail) 5 % - 15% RCT for outpt 
treatment of cellulites
10% - 30% [17], [18]
Risk of complicated inpt course (1-Inptunc) 1- 4% Retrospective review 2% - 10% [19]
Risk of disability after hand infection/surgery 
(CompDis)
5% Retrospective review 1% - 10% [20]
Risk of death w/ complicated infection (1-CompRec) 3% Survey Estimate 2% - 3% [2]
Antibiotic side effects (ShortSE; LongSE) 5% - 34% RCT 5% - 34% [17], [18]
Inpt, Inpatient; Inf, infection; Outpt, Outpatient; RCT, randomized, double-blinded control trial; Rx, perscription
Table 2. Cost data used in model
HCUP Inpatient Charge 2003 Charge (Dollar)
Diagnosis
682.0 Cellulitis of face  10,644.00 
682.4 Cellulitis of hand  12,252.00 
682.9 Cellulitis, other  14,837.00 
038.9 Septicemia  29,654.00 
Procedure
86.04 Other Skin & Subq Incision 
and Drainage
 16,648.00 
86.89 Skin Repair & Plastic Recon-
struction
 25,868.00 
Medicare Charge  2005 Charge (Dollars)
Outpatient Visit- Level 3  1,143.00
HCUP, Healthcare Costs and Utilization Project
the infection. The analysis assumed that a broad-spectrum 
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for three days as the method of prophylactic treatment. All 
clinical outcomes were considered to their completion, and it 
was assumed that all costs and benefits occurred within one 
year of the bite and thus were not subject to discounting. 
Randomized controlled study design
A randomized, double-blind controlled trial was 
conducted to compare the outcomes of dog bite wounds 
in patients given three days of prophylactic amoxicillin-
clavulanic acid versus placebo. The study was approved by 
both the University of California San Francisco (UCSF) and 
Stanford University Institutional Review Boards. 
Study Setting and Population
This study was conducted at the ED of the UCSF and 
Stanford University Medical Center (SUMC), with a 
combined annual census of 75, 000 visits per year. The study 
periods were from August 2003 – March 2006 (UCSF) and 
October 2004 – March 2006 (SUMC). 
All dog bites, regardless of site were considered for 
enrollment. Patients were excluded if they met any of 
these criteria: 1) wounds over 12 hours old at presentation 
or already infected; 2) patients with immunosuppression; 
3) patients with a penicillin allergy; and 4) wounds with 
suspected neurovascular, tendon, joint or bone injury.
Randomized controlled study protocol
In order to consider all eligible wounds and maximize 
patient recruitment, patients with dog bites were identified 
through a real time notification and tracking system of all 
ED patients, previously described.14 The notification system 
screened all chief complaints on a tracking system 24/7, and 
the research coordinator was paged when a patient registered 
with “dog” or “bite” in the complaint. The coordinator 
then called to verify it was a dog bite and request patient 
enrollment. The emergency medicine physician obtained 
informed consent from the patient and enrolled the patient 
into a secure web-based system. The requested demographic, 
insurance, and visit data for this study was automatically sent 
to the research database and the appropriate fields populated. 
Once the consent was printed, signed and verified, the form 
randomized the patient to a treatment group based on patient 
weight via a computerized randomization code based in 
blocks of eight, and stratified according to weight to include 
children. Three-day courses of blinded medication was 
prepared by pharmacy and distributed to the patient in the ED 
with the first medication dose given in the ED. The physician 
completed the structured web-based data entry form. Printed 
standardized custom discharge sheets with instructions for 
taking medications, signs and symptoms of infection and 
when to follow-up were provided to every patient. 
Outcome Measures
Patients were to call investigators or return to the ED 
if signs of infection developed. All patients underwent 
structured phone follow-up after 14 days during which they 
were queried as to: 1) if they had developed signs of infection 
(redness or discharge) and 2) whether any practitioner 
treated the wound with antibiotics for wound infection. This 
determination of infection and treatment was confirmed with 
the treating physician and was used as the primary outcome 
for the study for several reasons. The physicians making 
those determinations were blind to randomization and initial 
treatment, and in our cost model treatment decisions are 
what drive costs. Patient opinion as to whether they thought 
the wound was infected was not considered an outcome if it 
healed without any further treatment. 
Data Analysis
Demographic and clinical characteristics in the 
randomized, double-blind controlled trial (RCT) were 
determined by t-tests, chi-square and Fisher’s exact tests as 
appropriate. The RCT analyses were conducted using SPSS 
11.0 (Chicago, Ill). The cost model and related sensitivity 
analysis was done in TreeAge Software 4.0 (Williamstown, 
Mass).
RESULTS
Study subjects
Figure 2 is a CONSORT diagram of patient enrollment. 
A total of 230 consecutive patients with dog bites presented 
during the study period. Of these, 84 patients (36.5%) were 
ineligible due to the exclusion criteria outlined above. Out 
of the remaining 146 (63.5%), six were missed and 43 
refused enrollment. Ninety-seven patients (42% overall) were 
consented for the study and three subsequently withdrew or 
were not available for follow-up (Figure 2).
Results of Randomized Controlled Trial
Table 3 compares the patient demographic and wound 
characteristics of those that received prophylactic amoxicillin-
clavulanic acid with those that received a placebo. The 
patients were of similar age and gender. The wounds of the 
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Figure 2. CONSORT diagram for the randomized control trial on 
the use of prophylactic antibiotics for dog bitesWestern Journal of Emergency Medicine  439  Volume XI, no. 5  :  December 2010
two groups were similar with regard to length and time from 
injury, though the placebo group tended to have a greater 
but non-significant proportion of full thickness, sutured and 
facial wounds (Table 3). None of the 48 wounds treated with 
antibiotics became infected, whereas two of the 46 wounds 
in the placebo group became infected for a difference of 
4% (95% CI 4%-14%) between the two groups. The overall 
infection rate was 2% (95% CI 0-7%) and both infected 
wounds occurring in the placebo group were sutured, 
including one on the face and the other on the neck. Both were 
diagnosed two days after enrollment. 
Results of the Sensitivity Analysis
Results of the sensitivity analysis are summarized 
in Figure 3. This graph shows the cost effectiveness of 
antibiotics at each baseline rate of infection from 0 to 10% 
given the corresponding rate of infection in the treated group. 
The diagonal line is the threshold for which it becomes 
beneficial to treat with prophylactic antibiotics. The cost 
model recommends treating wounds at greater than 5% risk 
of infection (even if they had only a small benefit of about 
1-2%). It is likely not cost effective to treat wounds with less 
than 5% risk of infection and never at levels below 3%. 
LIMITATIONS 
The high number of eligible patients who refused to 
participate and the fact we excluded wounds with suspected 
tendon injuries or fractures could have affected the low 
number of infections we found in our study. However we did 
include certain high-risk wounds such as those that were 
punctures or on extremities.4 There is also no clear validated 
outcome measure to determine traumatic wound infection. 
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Failure to use a consistent validated outcome measure has 
limited previous studies and corresponding systematic 
reviews. The Centers for Disease Control (CDC) has a set of 
clinical and lab criteria to try to standardize the reporting of 
surgical site infections. This criterion includes the treating 
physician’s assessment.15 It was impractical for us to get all 
patients follow-up so that we could apply the objective CDC 
criterion, but for our study we did use the determination of the 
treating physician since it was a blinded assessment and also 
fit the outcome in our cost model. 
Cost models are based on assumptions and tested across a 
range of sensitivity analysis as outlined in table 1. In the end, 
the assumptions need to make clinical sense and are estimated 
based on available data and tested in a sensitivity analysis 
(Figure 3). For example, we surmised that 90% of infections 
would initially get treated as outpatients after looking at 
published data and our institutional numbers.10 It may be 
possible that more than 10% would get admitted for an 
infection, and if the number was higher the threshold to treat 
with prophylactic antibiotics would be higher (i.e., more 
money could be saved by preventing both infections and the 
increased costs of hospital admission).
Finally, while our clinical trial is small and not sufficiently 
powered by itself to find a difference, it will add to the 
existing literature to allow for more concordant and accurate 
systematic reviews and meta-analyses. The results are also 
useful to make treatment recommendations when they are 
applied through the cost model with sensitivity analysis 
(equivalent to 95% CI).
DISCUSSION
Our study showed that the current rate of infection from 
dog bite wounds is lower than reported in most prior studies, 
and our associated cost model showed that if the rate of 
Table 3. Characteristics and outcomes of study patients in the 
randomized, double-blind controlled trial
Antibiotics
N=48
Placebo
N=46
Difference 
(95% CI)
Age (years) 34 31 3 (-5 – 11)
% Male 56 61 5 (-2 – 2)
Length (centimeter) 2.1 1.6 0.5 (- 0.2-
1.2)
Time from Injury
(minutes)
176 188 12 (-109–
84)
% Full thickness
(through dermis)
56 66 10 (-3 – 10)
% Non-facial 81 64 17 (-0.6 – 
33)
% Closed 17 32 15 (-2 – 30)
% Infected 0 4 4 (-1 – 4.5)
Figure 3. Sensitivity analysis of cost analysis comparing benefits 
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infection is less than 3-5% there is little value in the use of 
prophylactic antibiotics. This has led us to believe that we 
should focus on determining factors associated with high-risk 
wounds so that we can appropriately use prophylactic 
antibiotics.
From our analysis it is clear that the value of antibiotic 
use is related to the actual rate of infection and the drug’s 
effect on preventing infections. For example, three days of 
amoxicillin-clavulanic acid costs about $30 (assuming $5 a 
pill), whereas the cost of developing an infection that requires 
a return visit to the ED, probable intravenous antibiotics and 
possible admission costs thousands of dollars. At the extremes, 
if 20% of patients develop infections and even 1% could be 
prevented with a short course of prophylactic antibiotics, the 
front-end cost of antibiotics in all cases is minimal compared 
to the large cost of treating infections that do occur. In that 
case only a small benefit (1%) would be needed to be cost 
effective. However, as the baseline rate of infection becomes 
lower in the population, it is harder to achieve a benefit with 
antibiotics. Figure 3 demonstrates that if the infection rate is 
8%, there must to be a 3% decrease in the infection rate (to 
5%) to be cost-effective to treat people with antibiotics. At a 
5% baseline rate, there would need to be a 3% decrease to be 
cost-effective, which translates to an impractical 60% relative 
reduction in infections. At levels of infection less than 3% it is 
never cost effective to treat since the threshold line is already 
reached.
Our randomized controlled trial found that the overall 
infection rate of dog bite wounds was 2% (95% CI 0-7%) with 
a difference of 4% (95% CI -1-4.5%) between treatment and 
placebo groups. Based on the cost-model, it is not cost 
effective to give prophylactic antibiotics at 2%, though it may 
be justifiable at the upper end of the 95% CI of 7%. Our rate 
of 2% is lower than the most current reported infection rates 
of 5-10%4 but similar to that found in other studies.2,5 Several 
factors may account for this. We used a standardized definition 
of wound infection and a single agent known to be effective 
against the pathogens in dog bites. Previous studies used a 
variety of antibiotics (trimethoprim-sulfamethoxazole, 
cephalexin and erythromycin) with questionable efficacy 
against organisms such as Pasteurella multocida.5,9 These 
studies also did not use a consistent method of determining 
outcomes. Furthermore, the studies included in a prior meta-
analysis5 and Cochrane review9 were limited by design and 
lack of techniques related to improvement in wound cleansing 
that have occurred over the last 30 years, particularly 
irrigation. While the value, timing and route of antibiotic 
prophylaxis can be argued, the benefit of antibiotics is 
probably dwarfed by proper irrigation and its effect on wound 
colonization, which is the prime determinant of infection.16 
Since the publication of most of these studies there have been 
great improvements in wound irrigation and care. 
A randomized controlled multi-center trial of sufficient 
power may address the issue of antibiotic effectiveness. If an 
absolute risk reduction of 3% can be shown, prophylactic 
antibiotic use would be cost-effective. However, given the low 
rate of wound infection, conducting a randomized controlled 
trial to determine if antibiotics could significantly decrease 
infection would require nearly 7,000 patients and a cost too 
great to warrant such a trial. It is also clear that different dog 
bite wounds have different risks, and assuming them to be of 
equal risk in treatment decisions makes little clinical sense. 
We believe further research should focus on identifying 
factors associated with high-risk wounds. Our trial and 
previous literature suggest a small trend of benefit from 
antibiotic prophylaxis regardless of trial limitations. The 
results of this trial indicate that the baseline rate of wound 
infection is low, especially among low-risk wounds. Future 
studies should try to identify wounds that have a high risk of 
infection (above 3-5%) that would benefit from prophylactic 
antibiotics. For example, 13% of untreated sutured wounds got 
infected in this study suggesting they are at high-risk. There 
are currently no tools or decision guidelines to predict which 
bites are high-risk and likely to become infected. A set of 
clinical predictors to identify wounds at high risk of infection 
is needed and would be the next logical step to address the 
controversial issue of prophylactic antibiotics and guide 
physician management decisions.
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